TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. In December 2017, we licensed the rights to develop and commercialize TTP273 in China and certain Pacific Rim territories to Huadong Medicine.
GLP-1 is a member of the incretin family of neuroendocrine peptide hormones secreted from L-cells of the intestine in response to food ingestion. GLP-1 has multiple metabolic effects that are attractive for an anti-diabetic agent, which have been validated by existing injectable peptide GLP-1R agonists.
TTP273 has completed a 3 month phase 2 study in patients with type 2 diabetes where it demonstrated a statistically significant reduction in HbA1c. TTP273 was well-tolerated, with negligible incidences of nausea and vomiting across all arms of the study. Trends towards weight loss were also observed.
Presentations and Posters
Links to the following publications and presentations, which are located on outside websites, are provided for informational purposes only and do not constitute the opinions or views of vTv Therapeutics
- Valcarce C., Dunn I., Freeman J. Effects of the Oral, Small Molecule GLP-1R Agonist, TTP273, on Patients with Stage 2 Hypertension: Results from a Post-Hoc Analysis of the Phase 2 LOGRA Study; American Diabetes Association 79th Scientific Sessions in San Francisco, CA, June 7-11, 2019
- Freeman J., Dunn I., Valcarce C. Beyond Topline Results for the Oral (Non-Peptide) GLP-1R Agonist TTP273 in Type 2 Diabetes: How much and When?; 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) held in Lisbon, Portugal, September 11–15, 2017
- Freeman J., Soeder T., Dunn I., Valcarce C. Is Less More? Learning to Dose the Oral, Nonpeptide GLP-1R Agonist, TTP273 in Type 2 Diabetics; Presented at the American Diabetes Association 77th Scientific Sessions in San Diego, CA, June 9-13, 2017
- Freeman J., Dvergsten C., Dunn I., Valcarce C. TTP273, Oral (Nonpeptide) GLP-1R Agonist: Improved Glycemic Control without Nausea and Vomiting in Phase 2; Presented at the American Diabetes Association 77th Scientific Sessions in San Diego, CA, June 9-13, 2017
- Freeman J, Agolory J, and Valcarce C. Preclinical Findings with Oral GLP-1 Receptor Agonist TTP273 Reinforce Importance of Neuro-Enteroendocrine Signaling; Presented at the American Diabetes Association 76th Scientific Sessions, June 12, 2016, New Orleans, Louisiana
- Freeman J, Gustafson S, Dunn I, Burstein A, and Valcarce C. Oral Small Molecule GLP-1 Receptor (GLP-1R) Agonists for Type 2 Diabetes (T2DM) with Negligible Nausea and Vomiting; Presented at the Keystone Symposia on New Therapeutics for Diabetes and Obesity, April 18, 2016, La Jolla, California – View Presentation Slides
- Freeman J, Weaver S, Davis S, Rao M, Quada J, Santhosh K, Yokum S, Polisetti D, Andrews R, Tabrizifard S, Sturchler E, McDonald P, Agolory J, Gustafson S and Valcarce C. TTP273: Oral, G protein Pathway Selective Clinical-Stage GLP-1 Receptor (GLP-1R) Agonist; poster presented at the Keystone Symposia on G-Protein Coupled Receptors: Structure, Signaling and Drug Discovery, held in Keystone, Colorado. February 22, 2016
- Gustavson, S.TTP273, an Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Notably Reduces Glycemia in Subjects with Type 2 Diabetes Mellitus (T2DM); (Abstract # 155-OR) Presented at the 74th Annual Scientific Session of the American Diabetes Association, June 13, 2014, San Francisco, California
- Gustavson, S.TTP054, a Novel, Orally-Available Glucagon-like Peptide-1 (GLP-1) Agonist, Lowers HbA1c in Subjects with Type 2 Diabetes Mellitus (T2DM); (Abstract # 156-OR) Presented at the 74th Annual Scientific Session of the American Diabetes Association, June 13, 2014, San Francisco, California